AnaptysBio (NASDAQ:ANAB) Upgraded to “Strong-Buy” at Wolfe Research

AnaptysBio (NASDAQ:ANAB) was upgraded by investment analysts at Wolfe Research to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other analysts have also recently weighed in on the company. BTIG Research cut AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. Guggenheim dropped their price objective on AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. Truist Financial dropped their price objective on AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. Wedbush reaffirmed an “outperform” rating and set a $40.00 price objective on shares of AnaptysBio in a report on Monday. Finally, UBS Group raised their price objective on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $40.08.

AnaptysBio Trading Down 0.9 %

Shares of NASDAQ ANAB opened at $16.51 on Monday. The stock has a market cap of $502.40 million and a P/E ratio of -2.72. AnaptysBio has a 12-month low of $12.51 and a 12-month high of $41.31. The business’s fifty day simple moving average is $17.23 and its 200-day simple moving average is $26.89.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.72) by $0.58. The business had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. On average, equities analysts forecast that AnaptysBio will post -6.08 EPS for the current fiscal year.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, Director Ecor1 Capital, Llc acquired 6,646 shares of the stock in a transaction on Thursday, January 2nd. The shares were bought at an average price of $12.95 per share, with a total value of $86,065.70. Following the acquisition, the director now owns 7,880,094 shares of the company’s stock, valued at $102,047,217.30. This trade represents a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 33.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On AnaptysBio

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Y Intercept Hong Kong Ltd acquired a new stake in shares of AnaptysBio during the 4th quarter valued at approximately $311,000. Rhumbline Advisers lifted its position in shares of AnaptysBio by 3.8% during the 4th quarter. Rhumbline Advisers now owns 30,077 shares of the biotechnology company’s stock valued at $398,000 after acquiring an additional 1,111 shares during the period. Jennison Associates LLC lifted its position in shares of AnaptysBio by 1.6% during the 4th quarter. Jennison Associates LLC now owns 269,131 shares of the biotechnology company’s stock valued at $3,563,000 after acquiring an additional 4,242 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of AnaptysBio by 11.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 644 shares during the period. Finally, SG Americas Securities LLC lifted its position in shares of AnaptysBio by 35.0% during the 4th quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 4,231 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.